Published 11 hours ago • loading... • Updated 1 hour ago
Ebola Vaccine Trial Begins In DR Congo
The Tumaini trial will test Ervebo and other candidates to see whether they protect against the Bundibugyo strain, WHO said.
On Friday, the first participants were vaccinated in Bunia, DRC, in the Tumaini Ebola vaccine trial. WHO chief Tedros Adhanom Ghebreyesus said the trial aims to determine if vaccine candidates can effectively target the Bundibugyo virus.
The DRC's worst Ebola outbreak has surpassed 9,700 cases, with deaths exceeding 4,600. A primary challenge remains the absence of approved vaccines or treatments for the Bundibugyo species of Ebola driving this epidemic.
Researchers will initially test the Everbo vaccine, approved for the Zaire strain, for potential cross-protection against Bundibugyo. Future phases will incorporate two Bundibugyo-specific candidates: a ChAdOx1 vector vaccine from the University of Oxford and an mRNA jab from US-based Moderna.
The World Health Organization is supporting this DRC-led effort to evaluate the vaccines and provide critical data on safety and efficacy. Officials hope the trial framework will eventually help save lives during the ongoing health crisis.
Named Tumaini, which means 'hope' in Swahili, the trial framework allows researchers to test multiple vaccines simultaneously. This scientific approach aims to identify whether existing or new candidates can mitigate the threat posed by the Bundibugyo virus.
WHO chief Tedros Adhanom Ghebreyesus said on X: 'Science gives us hope. Today, in Bunia DRC, the first participants were vaccinated in a new Ebola vaccine trial called Tumaini, which means 'hope' in Swahili.'
The epidemic has already left more than 4,600 people dead in the Democratic Republic of the Congo. The first clinical trial of an Ebola vaccine in the Democratic Republic of the Congo is...